Investors

investor people image

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Osiris Announces a Peer-Reviewed Publication of a Scientific Study Reporting Antimicrobial Properties of Human Cryopreserved Viable Amniotic Membrane
COLUMBIA, Md. , Oct. 23, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (Pink Sheets:OSIR), a leading regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced today a scientific publication of "Antimicrobial Peptides
View HTML
Toggle Summary Osiris Therapeutics to Present 10 Advanced Clinical and Scientific Abstracts, Including an Exclusive Oral Presentation on its New Ambient Viable Tissue Preservation Technology
Experts to host a variety of presentations at Symposium on Advanced Wound Care Fall Meeting, October 20 - October 22, 2017, in Las Vegas, Nevada
View HTML
Toggle Summary Osiris Announces a Peer-Reviewed Publication Reporting the Use of Placental Membranes for Refractory Cutaneous Sinus Tracts of Surgical Origin
COLUMBIA, Md. , Oct. 05, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (Pink Sheets:OSIR), a leading regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced today that a new peer reviewed manuscript entitled
View HTML
Toggle Summary Osiris Appoints Linda Palczuk to serve as its President & CEO
COLUMBIA, Md., June 26, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (Pink Sheets:OSIR) is pleased to announce that its Board of Directors has appointed Ms. Linda Palczuk, age 55, to serve as President and CEO, effective July 10, 2017. She will stand for election to the Board of Directors at the next shareholder meeting.  Ms. Palczuk had
View HTML
Toggle Summary Osiris Announces Electronically Available Case Study in a Peer-Reviewed Journal:  Open Surgical Implantation of a Viable Cryopreserved Placental Membrane after Decompression and Neurolysis of Common Peroneal Nerve
COLUMBIA, Md., June 14, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (Pink Sheets:OSIR), a leading regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced today that a new peer reviewed manuscript entitled "Open Surgical Implantation of a Viable Cryopreserved
View HTML
Toggle Summary Osiris Appoints David White to its Board of Directors
COLUMBIA, Md., May 31, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (Pink Sheets:OSIR) is pleased to announce that its Board of Directors, at a Board Meeting on May 30th, 2017, appointed Mr. David White as a director, upon recommendation of the Nominating Committee.  The Board of Directors also appointed Mr. White as a member of the Audit
View HTML
Toggle Summary Osiris Announces Scientific Manuscript Comparing Impact of Preservation Methods on Tissue Integrity and Functionality is Available Electronically in Peer-Reviewed Journal
COLUMBIA, Md., April 13, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (Pink Sheets:OSIR), a leading regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced today that that a new peer-reviewed manuscript entitled "Understanding the Impact of Preservation Methods
View HTML
Toggle Summary Osiris Therapeutics to Present 29 Advanced Clinical and Scientific Abstracts, Including a Late-Breaking Abstract on its New Ambient Viable Tissue Preservation Technology
COLUMBIA, Md., April 04, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (Pink Sheets:OSIR), a leading regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, will present advanced clinical and scientific research at the Symposium on Advanced Wound Care (SAWC) and Wound
View HTML
Toggle Summary Osiris Therapeutics Announces Change in its Board of Directors
COLUMBIA, Md., March 31, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (Pink Sheets:OSIR), announced today the passing of one of its Board Members, Yves Huwyler. "It deeply saddens me to announce the untimely loss of a dear friend and most valued Partner and Director Yves Huwyler, who died at the age of 44, after a long struggle with
View HTML
Toggle Summary Osiris Therapeutics Launches Prestige™ Lyotechnology, a Novel Method for Ambient Storage of Living Cells and Tissues
COLUMBIA, Md., March 30, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (Pink Sheets:OSIR), a leading regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced today that it has developed cutting edge technology enabling the preservation of living cells and tissues
View HTML